Douglas Miehm
Stock Analyst at RBC Capital
(4.03)
# 1,709
Out of 5,043 analysts
415
Total ratings
50.3%
Success rate
5.4%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Reiterated: Hold | $25 → $37 | $36.39 | +0.30% | 7 | Oct 9, 2026 | |
| BLCO Bausch + Lomb | Reiterated: Buy | $21 | $17.15 | +22.45% | 39 | Oct 8, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Reiterated: Hold | $12.83 | $8.60 | +49.18% | 105 | Oct 8, 2026 | |
| TSX: APTX Apotex Health Corp. | Reiterated: Buy | $43.00 | $30.54 | +40.80% | 4 | Oct 6, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Reiterated: Buy | $21.00 → $22.00 | $18.19 | +20.95% | 43 | Sep 22, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $345 | $295.00 | +16.95% | 21 | Aug 9, 2026 | |
| AUPH Aurinia Pharmaceuticals | Reiterated: Hold | $15 → $16 | $16.22 | -1.36% | 44 | Aug 7, 2026 | |
| TSX: DR Medical Facilities Corporation | Reiterated: Hold | $19.00 | $14.94 | +27.18% | 47 | Aug 7, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Reiterated: Buy | $9.50 → $11.00 | $10.73 | +2.52% | 28 | Aug 7, 2026 | |
| MNKD MannKind | Reiterated: Hold | $4.75 | $3.42 | +38.89% | 10 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.00 | $4.15 | +68.67% | 22 | May 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.71 | $14.91 | -48.27% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.46 → $3.5 | $0.5444 | +542.91% | 30 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $19 | $3.59 | n/a | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 | €77.10 | n/a | 3 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $7.19 | n/a | 6 | Aug 4, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $2.3 | $0.000001 | n/a | 2 | Nov 6, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $9.89 | n/a | 1 | Feb 5, 2009 |
Pacira BioSciences
Oct 9, 2026
Reiterated: Hold
Price Target: $25 → $37
Current: $36.39
Upside: +0.30%
Bausch + Lomb
Oct 8, 2026
Reiterated: Buy
Price Target: $21
Current: $17.15
Upside: +22.45%
Bausch Health Companies Inc.
Oct 8, 2026
Reiterated: Hold
Price Target: $12.83
Current: $8.60
Upside: +49.18%
Apotex Health Corp.
Oct 6, 2026
Reiterated: Buy
Price Target: $43.00
Current: $30.54
Upside: +40.80%
DRI Healthcare Trust
Sep 22, 2026
Reiterated: Buy
Price Target: $21.00 → $22.00
Current: $18.19
Upside: +20.95%
Ligand Pharmaceuticals
Aug 9, 2026
Reiterated: Buy
Price Target: $345
Current: $295.00
Upside: +16.95%
Aurinia Pharmaceuticals
Aug 7, 2026
Reiterated: Hold
Price Target: $15 → $16
Current: $16.22
Upside: -1.36%
Medical Facilities Corporation
Aug 7, 2026
Reiterated: Hold
Price Target: $19.00
Current: $14.94
Upside: +27.18%
Knight Therapeutics Inc.
Aug 7, 2026
Reiterated: Buy
Price Target: $9.50 → $11.00
Current: $10.73
Upside: +2.52%
MannKind
Aug 6, 2026
Reiterated: Hold
Price Target: $4.75
Current: $3.42
Upside: +38.89%
May 10, 2026
Reiterated: Buy
Price Target: $7.00
Current: $4.15
Upside: +68.67%
Mar 19, 2026
Reiterated: Buy
Price Target: $7.71
Current: $14.91
Upside: -48.27%
Nov 19, 2025
Reiterated: Buy
Price Target: $2.46 → $3.5
Current: $0.5444
Upside: +542.91%
Oct 8, 2021
Reiterated: Hold
Price Target: $18 → $19
Current: $3.59
Upside: n/a
Jun 23, 2021
Reiterated: Buy
Price Target: €22.00
Current: €77.10
Upside: n/a
Aug 4, 2016
Reiterated: Hold
Price Target: $1
Current: $7.19
Upside: n/a
Nov 6, 2013
Rated: Hold
Price Target: $3 → $2.3
Current: $0.000001
Upside: n/a
Feb 5, 2009
Upgraded: Buy
Price Target: n/a
Current: $9.89
Upside: n/a